Biotech venture financing upturn of 70.9% QoQ in 3rd quarter 2025
GlobalData’s Venture Capital Investment Trends In Pharma – Q3 2025 report reveals that the biotech industry witnessed a 70.9% increase in total venture financing deal value from $1.8 billion in second-quarter 2025 to $3.1 billion in third-quarter 2025.
This uptick signals improving investor sentiment, reflecting renewed confidence in biotech innovation and growth prospects despite policy uncertainty, market headwinds, and recent funding constraints in the USA, says the pharma analytics company.
Biotech funding recovery was seen in 2024 fueled by interest rate cuts, with the trend continuing to first-quarter 2025. However, the return of the Trump administration in January 2025 contributed to a further challenging environment, as tariffs, drug pricing pressures, funding cuts to the National Institutes of Health (NIH) and layoffs at the FDA and CDC created market uncertainty.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze